ProCE Banner Activity

CME

Expert Guide: What’s New and Next for Novel Targeted Therapies in Relapsed/Refractory Follicular Lymphoma

Video

On-demand webcast of expert faculty presentation and case discussion on the emerging novel targeted therapies—what’s new and what’s next—for treating patients with relapsed or refractory follicular lymphoma.

Physicians: Maximum of 2.00 AMA PRA Category 1 Credits

Released: December 19, 2023

Expiration: December 18, 2024

Share

Faculty

Julie M. Vose

Julie M. Vose, MD, MBA

Newmann M. and Milde E. Harris Professor
Chief, Hematology/Oncology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Peter Martin

Peter Martin, MD

Chief, Lymphoma Program
Professor of Medicine
Weill Cornell Medicine
Meyer Cancer Center
New York, New York

Sonali M. Smith

Sonali M. Smith, MD, FASCO

Elwood V. Jensen Professor of Medicine
Chief, Section of Hematology/Oncology
Co-Leader, Cancer Service Line
The University of Chicago
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Genentech, a member of the Roche Group; Genmab; Ipsen Biopharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc.

Genentech, a member of the Roche Group

Genmab

Ipsen Biopharmaceuticals Inc

Regeneron Pharmaceuticals, Inc

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with relapsed/refractory follicular lymphoma.

Program Learning Goal

The goal of this activity is to improve the knowledge, competence, and performance of physicians and other healthcare professionals to optimize diagnosis and management of patients with relapsed/refractory follicular lymphoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate currently available clinical data on novel targeted therapies to treat patients with relapsed/refractory follicular lymphoma

  • Plan the optimal sequence of antibodies, CAR T-cell therapy, or epigenetic modifiers for patients with relapsed/refractory follicular lymphoma based on available evidence, as well as guideline and expert recommendations

  • Identify patients with relapsed/refractory follicular lymphoma who are eligible for enrollment on a clinical trial

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Julie M. Vose, MD, MBA

Newmann M. and Milde E. Harris Professor
Chief, Hematology/Oncology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Julie M. Vose, MD, MBA: consultant/advisor/speaker: AbbVie, Genmab, MEI Pharma; researcher: Epizyme, Kite, Loxo, Novartis. 

Primary Author

Peter Martin, MD

Chief, Lymphoma Program
Professor of Medicine
Weill Cornell Medicine
Meyer Cancer Center
New York, New York

Peter Martin, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Beigene, Daiichi Sankyo, Genentech, Janssen, Merck, PeproMene.

Sonali M. Smith, MD, FASCO

Elwood V. Jensen Professor of Medicine
Chief, Section of Hematology/Oncology
Co-Leader, Cancer Service Line
The University of Chicago
Chicago, Illinois

Sonali M. Smith, MD, FASCO: consultant/advisor/speaker: Bristol Myers Squibb, Gilead, Ono Pharmaceutical. 

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from December 19, 2023, through December 18, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

 

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.